SLNO - Soleno Therapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.64
|
Rev Est: $88.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$105.20
DETAILS
HIGH:
$125.00
LOW:
$60.00
MEDIAN:
$114.00
CONSENSUS:
$105.20
UPSIDE:
168.64%
Market Cap:
2.10B
Volume:
885,274
Avg Volume:
1,511,005
52 Week Range:
36.67-90.32
Sector:
Healthcare
Industry:
Biotechnology
Beta:
-3.18
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
115
IPO Date:
2014-11-13
EPS (TTM):
-4.38
P/E Ratio:
-10.27
Revenue (TTM):
N/A
Total Assets:
330.97M
Total Debt:
52.83M
Cash & Equiv:
87.93M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-56.2%
Debt/Equity:
0.22
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $0.47 | $0.06 | +717.4% | $66.0M | $88.5M | -25.4% |
| 2025-08-06 | $-0.09 | $-0.53 | +83.0% | $32.7M | $39.3M | -17.0% |
| 2025-05-07 | $-0.95 | $-1.14 | +16.7% | — | — | — |
| 2025-02-27 | $-1.27 | $-0.63 | -101.6% | — | — | — |
| 2024-11-06 | $-1.83 | $-0.61 | -200.0% | — | — | — |
| 2024-08-07 | $-0.57 | $-0.63 | +9.5% | — | — | — |
| 2024-05-09 | $-0.59 | $-0.30 | -96.7% | — | — | — |
| 2024-03-06 | $-0.33 | $-0.31 | -6.5% | $3.4M | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1.55B) | 1.45M | 387,555 | 0 | 3.00M |
| Net Income | (175.85M) | (38.99M) | (24.07M) | (30.91M) | (24.64M) | (30.77M) | (13.34M) | (15.67M) | (12.07M) | (15.91M) | (13.87M) | (3.71M) |
| EPS | -4.38 | -2.36 | -2.87 | -5.81 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 |
| Total Assets | 330.97M | 180.69M | 26.50M | 35.55M | 64.98M | 38.17M | 43.15M | 39.02M | 5.56M | 8.20M | 8.40M | 1.59M |
| Total Debt | 52.83M | 403,000 | 155,000 | 457,000 | 139,000 | 305,000 | 0 | 0 | 0 | 0 | 101,529 | 13.99M |
| Cash & Equivalents | 87.93M | 169.68M | 14.60M | 21.30M | 49.22M | 20.73M | 23.10M | 17.10M | 2.73M | 5.49M | 7.96M | 1.27M |
| Operating Cash Flow | (69.10M) | (24.94M) | (20.78M) | (27.77M) | (25.22M) | (17.38M) | (11.68M) | (9.95M) | (13.50M) | (10.30M) | (4.48M) | (885,218) |
| Free Cash Flow | (69.31M) | (24.94M) | (20.79M) | (27.79M) | (25.23M) | (17.40M) | (11.69M) | (9.95M) | (13.54M) | (10.61M) | (4.52M) | (886,492) |
| FCF per Share | -1.73 | -1.51 | -2.48 | -5.23 | -6.04 | -7.64 | -8.36 | -16.63 | -65.47 | -84.38 | -266.64 | -47.45 |
| Book Value | 245.11M | 157.51M | 10.35M | 17.79M | 45.55M | 14.95M | 30.41M | 26.53M | 3.44M | 3.22M | (10.33M) | (37.86M) |
| Cash & ST Investments | 291.44M | 169.68M | 14.60M | 21.30M | 49.22M | 20.73M | 24.08M | 17.10M | 2.73M | 5.49M | 7.96M | 1.27M |
| ROC Equity | -0.72 | -0.25 | -2.33 | -1.74 | -0.54 | -2.06 | -0.44 | -0.59 | -3.51 | -4.93 | N/A | N/A |